Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Interstitial flow differentially increases patient-derived glioblastoma stem cell invasion via CXCR4, CXCL12, and CD44-mediated mechanisms.

Kingsmore KM, Logsdon DK, Floyd DH, Peirce SM, Purow BW, Munson JM.

Integr Biol (Camb). 2016 Dec 5;8(12):1246-1260.

PMID:
27775742
2.

Sustained radiosensitization of hypoxic glioma cells after oxygen pretreatment in an animal model of glioblastoma and in vitro models of tumor hypoxia.

Clarke RH, Moosa S, Anzivino M, Wang Y, Floyd DH, Purow BW, Lee KS.

PLoS One. 2014 Oct 28;9(10):e111199. doi: 10.1371/journal.pone.0111199. eCollection 2014.

3.

Novel anti-apoptotic microRNAs 582-5p and 363 promote human glioblastoma stem cell survival via direct inhibition of caspase 3, caspase 9, and Bim.

Floyd DH, Zhang Y, Dey BK, Kefas B, Breit H, Marks K, Dutta A, Herold-Mende C, Synowitz M, Glass R, Abounader R, Purow BW.

PLoS One. 2014 May 7;9(5):e96239. doi: 10.1371/journal.pone.0096239. eCollection 2014.

4.

A miR-297/hypoxia/DGK-α axis regulating glioblastoma survival.

Kefas B, Floyd DH, Comeau L, Frisbee A, Dominguez C, Dipierro CG, Guessous F, Abounader R, Purow B.

Neuro Oncol. 2013 Dec;15(12):1652-63. doi: 10.1093/neuonc/not118. Epub 2013 Oct 24.

5.

Diacylglycerol kinase α is a critical signaling node and novel therapeutic target in glioblastoma and other cancers.

Dominguez CL, Floyd DH, Xiao A, Mullins GR, Kefas BA, Xin W, Yacur MN, Abounader R, Lee JK, Wilson GM, Harris TE, Purow BW.

Cancer Discov. 2013 Jul;3(7):782-97. doi: 10.1158/2159-8290.CD-12-0215. Epub 2013 Apr 4.

6.

Frizzled receptors signal through G proteins.

Nichols AS, Floyd DH, Bruinsma SP, Narzinski K, Baranski TJ.

Cell Signal. 2013 Jun;25(6):1468-75. doi: 10.1016/j.cellsig.2013.03.009. Epub 2013 Mar 19.

7.

The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling.

Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O, Heller E, Deng H, Zou W, Craft CS, Wu K, Hirbe AC, Grabowska D, Eagleton MC, Townsley S, Collins L, Piwnica-Worms D, Steinberg TH, Novack DV, Conley PB, Hurchla MA, Rogers M, Weilbaecher KN.

J Clin Invest. 2012 Oct;122(10):3579-92. doi: 10.1172/JCI38576. Epub 2012 Sep 17.

8.

Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch.

Floyd DH, Kefas B, Seleverstov O, Mykhaylyk O, Dominguez C, Comeau L, Plank C, Purow B.

Neuro Oncol. 2012 Oct;14(10):1215-26. Epub 2012 Sep 7.

9.

The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors.

Kefas B, Comeau L, Floyd DH, Seleverstov O, Godlewski J, Schmittgen T, Jiang J, diPierro CG, Li Y, Chiocca EA, Lee J, Fine H, Abounader R, Lawler S, Purow B.

J Neurosci. 2009 Dec 2;29(48):15161-8. doi: 10.1523/JNEUROSCI.4966-09.2009.

10.

The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.

Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, Lanigan LG, Apicelli AJ, Xu Z, Prior JL, Eagleton MC, Piwnica-Worms D, Rogers MJ, Weilbaecher K.

Bone. 2009 May;44(5):908-16. doi: 10.1016/j.bone.2009.01.010. Epub 2009 Jan 23.

11.

Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases.

Xu Z, Hurchla MA, Deng H, Uluçkan O, Bu F, Berdy A, Eagleton MC, Heller EA, Floyd DH, Dirksen WP, Shu S, Tanaka Y, Fernandez SA, Rosol TJ, Weilbaecher KN.

J Biol Chem. 2009 Feb 13;284(7):4658-66. doi: 10.1074/jbc.M804812200. Epub 2008 Dec 5.

12.

Multiple facets of junD gene expression are atypical among AP-1 family members.

Hernandez JM, Floyd DH, Weilbaecher KN, Green PL, Boris-Lawrie K.

Oncogene. 2008 Aug 14;27(35):4757-67. doi: 10.1038/onc.2008.120. Epub 2008 Apr 21. Review.

13.

APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice.

Uluçkan O, Eagleton MC, Floyd DH, Morgan EA, Hirbe AC, Kramer M, Dowland N, Prior JL, Piwnica-Worms D, Jeong SS, Chen R, Weilbaecher K.

J Cell Biochem. 2008 Jul 1;104(4):1311-23. doi: 10.1002/jcb.21709.

14.

Random mutagenesis of the complement factor 5a (C5a) receptor N terminus provides a structural constraint for C5a docking.

Hagemann IS, Narzinski KD, Floyd DH, Baranski TJ.

J Biol Chem. 2006 Dec 1;281(48):36783-92. Epub 2006 Oct 5.

15.

C5a receptor oligomerization. II. Fluorescence resonance energy transfer studies of a human G protein-coupled receptor expressed in yeast.

Floyd DH, Geva A, Bruinsma SP, Overton MC, Blumer KJ, Baranski TJ.

J Biol Chem. 2003 Sep 12;278(37):35354-61. Epub 2003 Jun 30.

Supplemental Content

Loading ...
Support Center